More frequent extreme weather events, increasing political nationalism and growing economic inequality are making sustainable development goals harder to achieve. EURACTIV looked at the work of four frontier researchers to explore how a more sustainable future could look like.
Many regions of Europe for poor medical care because there is a lack of doctors, money or infrastrcture. The Commission is now considering how the structural funds can help in a targeted way. EURACTIV Germany reports.
Several pharmaceutical companies in Greece have threatened to stop supplying the market with innovative drugs and said they could even withdraw existing drugs as a result of an obligatory “discount” imposed by the Greek government and applied retroactively.
When chemicals are considered too dangerous to be tested on humans, animals have long been the answer to some scientific quandaries. The EU project ToxRisk will act as Europe's flagship for safety assessments that do not require the use of animals. EURACTIV Germany reports.
Three scientists from Japan, China and Ireland whose discoveries led to the development of potent new drugs against parasitic diseases including malaria and elephantiasis won the Nobel Prize for Medicine on Monday (5 October).
A new report on medicines shortages experienced in European healthcare systems published on Monday (17 November) by the European Association of Hospital Pharmacists (EAHP) reveals that over 86% of hospital pharmacists are experiencing difficulties in sourcing medicines in the EU.
France is spending too much money on medicine and needs to promote the use of generic drugs. The French Court of Auditors recommends offering doctors incentives to prescribe cheaper generics to achieve this and capping their prescription budgets.
The European Parliament voted in favour of the second Innovative Medicines Initiative (IMI2) on Tuesday (15 April), a multi-billion Euro research programme run jointly by the European Commission and the pharmaceutical industry.
One of the global financial crisis' consequences has been the lack of access to treatment for millions of Europeans. According to health promoters, alternative solutions to the problem may be the way forward.
Orphan drugs, pharmaceutical agents that are developed specifically to treat rare diseases, have the potential to generate as much lifetime revenue as drugs used for more common health conditions, according to a new study.